SVR12 of 99% Achieved With a Ribavirin-Free Regiment of ABT-450/r/Ombitasvir and Dasabuvir in HCV Genotype 1b-Infected Patients

Share
  • Twitter
  • Facebook
  • email
  • StumbleUpon
  • Delicious
  • Google Reader
  • LinkedIn
  • Google Bookmarks

    PRESIDENT’S PLENARY SESSION 1
    Monday, October 20
    8:00 am – 9:00 am
    (Terrace Ballroom)
    Moderators: Harry E. Sarles, Jr., MD, FACG
    John R. Saltzman, MD, FACG

    Oral 4: SVR12(sustained virologic response 12 weeks post-treatment) of 99% Achieved With a Ribavirin-Free Regiment of ABT-450/r/Ombitasvir and Dasabuvir in HCV Genotype 1b-Infected Patients
    2014 ACG International Award

    Andreas Maieron, MD, Massimo Puoti, MD, Jeffrey Enejosa, MD, Ziv Ben-Ari, MD, Gunnar Norkrans, MD, Manuel Romero-Gomez, MD, Wangang Xie, MD, PhD, Daniel Cohen, MD, Thomas Podsadecki, MD, Pietro Andreone, MD, Elisabeth Hospital, Linz, Austria, A.O. Ospedale Niguarda Ca Granda, Milan, Italy, AbbVie, Inc., North Chicago, IL, The Chaim Sheba Medical Center, Tel Hashomer, Israel, Sahlgrenska University Hospital, Göteborg, Sweden, Hospital Universitario Nuestra Senora De Valme, Seville, Spain, University of Bologna, Bologna, Italy.

    Read author insight and access abstract


    Embargo Policy

    All research presented at the ACG Annual Scientific Meeting is strictly embargoed until 8:00 a.m. on the first day of the Annual Meeting. For 2014, this is Monday, October 20 at 8:00 a.m. EDT.

    Share
    • Twitter
    • Facebook
    • email
    • StumbleUpon
    • Delicious
    • Google Reader
    • LinkedIn
    • Google Bookmarks